NCT01004354

Vitamin D Supplementation in Psychiatric Illnesses

Effect of Vitamin D Supplementation on the Metabolic Abnormalities of Second Generation Antipsychotics in Children and Adolescents

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: University of Massachusetts, Worcester · Academic / Other
• Sex: All
• Age: 10 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

Children and adolescents with psychiatric illnesses who are treated with medications called second generation antipsychotic agents (SGA) often gain excessive weight during their treatment with these medications. This weight gain may result in the development of features of the metabolic syndrome or frank diabetes mellitus. There is no consensus on the best way to prevent these complications. The investigators' hypothesis is that daily vitamin D supplementation in these patients will result in decreased levels of the markers of metabolic syndrome with associated reduction in waist circumference.

Detailed description

In this 8-week open label trial, we will enroll 10 subjects who fulfill the Inclusion Criteria.

Conditions

• Obesity
• Vitamin D Deficiency
• Psychosis
• Schizophrenia
• Schizoaffective Disorder

Interventions

Type	Name	Description
DRUG	Ergocalciferols	2000 international units by mouth daily for 8 weeks.

Timeline

• Start date: 2009-06-01
• Primary completion: 2010-06-01
• Completion: 2010-06-01
• First posted: 2009-10-29
• Last updated: 2017-11-06
• Results posted: 2012-02-10

Locations

1 site across 1 country: United States